(formerly Lexston Life Sciences Corp.)

CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED MAY 31, 2024 AND 2023

(EXPRESSED IN CANADIAN DOLLARS)



Independent Auditor's Report

To the Shareholders of:

LEXSTON MINING CORPORATION

(formerly Lexston Life Sciences Corp.)

Opinion

We have audited the consolidated financial statements of Lexston Mining Corporation (formerly Lexston Life Sciences Corp.) and its subsidiaries (collectively "the Company"), which comprise the consolidated statements of financial position as at May 31, 2024 and 2023, and the consolidated statements of operations and comprehensive loss, changes in shareholders' equity, and cash flows for the years then ended, and notes to the consolidated financial statements, including a summary of material accounting policies.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the financial position of the Company as at May 31, 2024 and 2023 and its financial performance and its cash flows for the years then ended in accordance with International Financial Reporting Standards ("IFRS").

Basis for Opinion

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Financial Statements* section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of the consolidated financial statements in Canada, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Material Uncertainty Related to Going Concern

We draw attention to Note 1 in the consolidated financial statements, which indicates that the Company used cash of \$523,178 for operating activities and incurred a net loss of \$867,713 during the year ended May 31, 2024, and as of that date, had accumulated losses since inception of \$4,379,742. As stated in Note 1, these events or conditions, along with other matters as set forth in Note 1, indicate that a material uncertainty exists that may cast significant doubt on the Company's ability to continue as a going concern. Our opinion is not modified in respect of this matter.

Key Audit Matters

Key audit matters are those matters, that in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

We have determined that there are no key audit matters to communicate in our auditor's report.

Other Information

Management is responsible for the other information. The other information comprises Management's Discussion and Analysis.

Our opinion on the consolidated financial statements does not cover the other information and will not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information identified above and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

We obtained Management's Discussion and Analysis prior to the date of this auditor's report. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

SERVICE

INTEGRITY

TRUST



SUITE 420

1501WEST BROADWAY

VANCOUVER, BRITISH COLUMBIA

CANADA V6J 4Z6

TEL: (604) 428-1866

FAX: (604) 428-0513

WWW.WDMCA.COM



Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with IFRS, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are
 appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the
 Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Company to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

The engagement partner on the audit resulting in this independent auditor's report is Mike Kao.

Chartered Professional Accountants

Vancouver, B.C. September 11, 2024



(formerly Lexston Life Sciences Corp.)
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
AS AT MAY 31, 2024 AND 2023
(Expressed in Canadian dollars)

		2024	2023
	Note	\$	\$
ASSETS			
Current assets			
Cash		390,405	510,995
Accounts receivable	5	9,057	6,350
Prepaid expenses and advances		54,000	240,325
Total current assets		453,462	757,670
Non-current assets			
Investment	8	1	1
Property and equipment	6	1	56,631
Exploration and evaluation assets	7	297,485	, <u> </u>
Total non-current assets		297,487	56,632
TOTAL ASSETS		750,949	814,302
LIABILITIES AND SHAREHOLDERS' EQUITY			
Current liabilities			
Accounts payable and accrued liabilities		39,869	11,207
Total current liabilities		39,869	11,207
21 1 1 1 1 1			•
Shareholders' equity	0	4.002.050	4 460 660
Share capital	9	4,963,050	4,163,662
Share-based payment reserves Deficit	10,11	127,772	151,462
		(4,379,742)	(3,512,029)
Total shareholders' equity		711,080	803,095
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY		750,949	814,302

Nature of operations and continuance of business (Note 1) Subsequent event (Note 15)

Approved and authorized for issuance by the Board of Directors on September 11, 2024:

/s/ Clinton Sharples	/s/ Jagdip Bal
Clinton Sharples, Director	Jagdip Bal, Director

(formerly Lexston Life Sciences Corp.)
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
FOR THE YEARS ENDED MAY 31, 2024 AND 2023
(Expressed in Canadian dollars)

		2024	2023
	Note	\$	\$
Operating expenses			
Advertising and promotion		102,704	172,900
Consulting fees	12	205,186	279,428
Exploration and evaluation expenditures	7	5,938	_
Management fees	12	69,524	188,825
Office and miscellaneous		1,584	3,640
Professional fees		148,695	96,274
Property investigation		62,993	_
Regulatory and transfer agent fees		59,564	65,538
Share-based compensation	10,11,12	75,625	129,886
Travel		2,469	578
Total operating expenses		734,282	937,069
Net loss before other expense		(734,282)	(937,069)
Other expense			
Unrealized loss on investment	8	_	(28,999)
Loss from continuing operations		(734,282)	(966,068)
Loss from discontinued operations	14	(133,431)	(142,676)
Net loss and comprehensive loss		(867,713)	(1,108,744)
Loss per share, basic and diluted		(0.03)	(0.04)
Weighted average number of shares outstanding,			
basic and diluted		31,891,480	28,580,063

(formerly Lexston Life Sciences Corp.)
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY
FOR THE YEARS ENDED MAY 31, 2024 AND 2023
(Expressed in Canadian dollars)

			Share-based		
	Share ca	apital	payment		
	Number	Amount	reserves	Deficit	Total
	of shares	\$	\$	\$	\$
Balance, May 31, 2022	11,746,727	3,276,996	793,059	(3,196,344)	873,711
Issuance of common shares pursuant to private placement	18,562,440	928,122	_	_	928,122
Share issue costs	_	(41,456)	21,576	_	(19,880)
Fair value of stock options granted	_	_	129,886	_	129,886
Transfer from reserves to deficit relating to cancelled options	_	_	(793,059)	793,059	, <u> </u>
Net loss for the year				(1,108,744)	(1,108,744)
Balance, May 31, 2023	30,309,167	4,163,662	151,462	(3,512,029)	803,095
Issuance of common shares pursuant to private placement	6,999,333	419,960	_	_	419,960
Share issue costs	-	(30,642)	13,005	_	(17,637)
Shares issued for exploration and evaluation assets	1,250,000	97,500	_	_	97,500
Fair value of stock options granted	, , , <u> </u>	, <u> </u>	75,625	_	75,625
Shares issued pursuant to exercise of options	2,475,000	245,070	(112,320)	_	132,750
Shares issued pursuant to exercise of warrants	900,000	67,500	· · · · ·	_	67,500
Net loss for the year	<u> </u>	<u> </u>	_	(867,713)	(867,713)
Balance, May 31, 2024	41,933,500	4,963,050	127,772	(4,379,742)	711,080

(formerly Lexston Life Sciences Corp.)
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED MAY 31, 2024 AND 2023
(Expressed in Canadian dollars)

	2024	2023
	\$	\$
OPERATING ACTIVITIES		
Net loss	(867,713)	(1,108,744)
Items not involving cash:		
Amortization	26,394	29,800
Loss on disposal of equipment	-	5,922
Share-based compensation	75,625	129,886
Unrealized loss on investment	-	28,999
Equipment for salaries and benefits	20.226	16,000
Impairment of property and equipment	30,236	_
Changes in non-cash operating working capital:		
Amounts receivable	(2,707)	31,215
Prepaid expenses and advances	186,325	(52,938)
Accounts payable and accrued liabilities	28,662	(67,881)
Net cash used in operating activities	(523,178)	(987,741)
INVESTING ACTIVITY		
Acquisition of exploration and evaluation assets	(199,985)	_
Net cash used in investing activity	(199,985)	_
FINANCING ACTIVITIES		
Net proceeds from private placement	402,323	908,242
Proceeds from exercise of stock options	132,750	_
Proceeds from exercise of warrants	67,500	_
Net cash provided by financing activities	602,573	908,242
Change in cash	(120,590)	(79,499)
Cash, beginning of year	510,995	590,494
Cash, end of year	390,405	510,995
Non-cash investing and financing activities:		
Fair value of broker warrants issued	13,005	21,576
Fair value of shares issued for acquisition	97,500	21,370
Transfer of fair value of stock options to share capital upon exercise	112,320	_

The accompanying notes are an integral part of these consolidated financial statements.

(formerly Lexston Life Sciences Corp.)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED MAY 31, 2024 AND 2023
(Expressed in Canadian dollars)

1. NATURE OF OPERATIONS AND CONTINUANCE OF BUSINESS

Lexston Mining Corporation (formerly Lexston Life Sciences Corp.) (the "Company") was incorporated on January 3, 2020 under the laws of the province of British Columbia. On October 16, 2023, the Company changed its name to Lexston Mining Corporation to reflect its change of business that include the acquisition and exploration of mineral properties. The address of the Company's registered and records office is 1150 – 789 West Pender Street, Vancouver, BC, V6C 1H2 and its principal place of business is 929 Mainland Street, Vancouver, BC V6B 1S3.

During the year ended May 31, 2024, the Company incurred a net loss of \$867,713 (2023 - \$1,108,744) and has used net cash in operating activities of \$523,178 (2023 - \$987,741). As at May 31, 2024, the Company has an accumulated deficit of \$4,379,742 (2023 - \$3,512,029). The Company expects to incur further losses in the development of its operations. While the Company has positive working capital, the ability of the Company to carry out its business objectives is dependent on its ability to secure continued financial support from related parties, to obtain public equity financing, or to ultimately attain profitable operations in the future. If and when the Company can attain profitability and positive cash flows is uncertain.

While the Company has been successful in securing financing in the past, there is no assurance that financing will be available in the future on terms acceptable to the Company. These consolidated financial statements do not give effect to any adjustments which would be necessary should the Company be unable to continue as a going concern and thus be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in these consolidated financial statements.

2. BASIS OF PREPARATION

a) Statement of compliance

These consolidated financial statements were approved by the Board of Directors and authorized for issue on September 11, 2024.

These consolidated financial statements have been prepared using accounting policies in compliance with International Financial Reporting Standards ("IFRS") issued by the International Accounting Standards Board and the interpretations of the International Financial Reporting Interpretations Committee. Certain comparative amounts have been reclassified to conform to the current year's presentation, refer to Note 14 for the discontinued operations disclosure.

b) Basis of presentation

These consolidated financial statements have been prepared using the historical cost basis, except for certain financial assets and liabilities which are measured at fair value as specified by IFRS for each type of asset, liability, income, and expense as set out in the accounting policies below.

c) Functional and presentation currency

These consolidated financial statements are presented in Canadian dollars. The functional currency is the currency of the primary economic environment in which an entity operates.

(formerly Lexston Life Sciences Corp.)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED MAY 31, 2024 AND 2023
(Expressed in Canadian dollars)

3. MATERIAL ACCOUNTING POLICIES

Principles of Consolidation

These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Egret Bioscience Ltd. ("Egret") and Zenalytic Laboratories Ltd. ("Zen").

The Company's consolidated financial statements include the accounts of all subsidiaries subject to control by the Company. Control is achieved when the Company has the power to, directly or indirectly, govern the financial and operating policies of an entity so as to obtain benefits from its activities. Subsidiaries are fully consolidated from the date on which control is obtained and continue to be consolidated until the date that such control ceases. Intercompany balances, transactions, and unrealized intercompany gains and losses are eliminated upon consolidation.

Use of Estimates and Judgments

The preparation of these consolidated financial statements in accordance with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Actual outcomes could differ from these estimates. The consolidated financial statements include estimates which, by their nature, are uncertain. The impacts of such estimates are pervasive throughout the consolidated financial statements and may require accounting adjustments based on future occurrences. Revisions to accounting estimates are recognized in the period in which the estimate is revised and the revision affects both the current and future periods.

Significant areas requiring the use of management estimates include the collectability of accounts receivable, carrying value of investment, the useful lives and carrying value of property and equipment and intangible assets, fair value of share-based compensation, and recoverability of unrecognized deferred income tax assets.

Significant judgments include the following:

- Assessment of whether the going concern assumption is appropriate which requires management to take into account all available information about the future, which is at least, but not limited to, 12 months from the end of the reporting period;
- Determining whether the acquisitions of Egret and Zen are a business combination or an asset acquisition. In a business combination, all identifiable assets, liabilities, and contingent liabilities acquired are recorded at their fair values. In determining the allocation of the purchase price in a business combination, including any acquisition related contingent consideration, estimates including market based and appraisal values are used. The contingent consideration is measured at its acquisition date fair value and included as part of the consideration transferred in the acquisition transaction. Contingent consideration that is classified as equity is not remeasured at subsequent reporting dates and its subsequent settlement is accounted for within equity; and
- Judgment with respect to the assessment of fair value of investment in a private company. The
 fair value of common shares in a private company is determined by valuation techniques such as
 recent arm's length transactions, option pricing models, or other valuation techniques commonly
 used by market participants.

Cash and cash equivalents

The Company considers all highly liquid investments with a maturity of three months or less at the time of issuance, are readily convertible to known amounts of cash, and which are subject to insignificant risks of changes in value to be cash equivalents.

(formerly Lexston Life Sciences Corp.)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED MAY 31, 2024 AND 2023
(Expressed in Canadian dollars)

3. MATERIAL ACCOUNTING POLICIES (continued)

Accounts receivable

The Company reviews the collectability of its accounts receivable and establishes an allowance for doubtful accounts based on the age of the receivable and factors that identify receivables that are at risk of non-collection.

Property and equipment

Property and equipment is recorded at historical cost less related accumulated depreciation and impairment losses. Cost is determined as the expenditure directly attributable to the asset at acquisition, only when it is probable that future economic benefits will flow to the Company and the cost can be reliably measured. When an asset is disposed of, its carrying cost is derecognized. All repairs and maintenance costs are charged to the consolidated statement of operations during the financial period in which they are incurred. The Company provides for depreciation of property and equipment on a straight-line basis unless otherwise noted using the following annual rates:

Computer equipment 3 years straight line Laboratory equipment 3 - 5 years straight line

Exploration and evaluation assets

The Company's exploration and evaluation assets are comprised of mineral properties owned by the Company and rights to ownership of mineral properties, which the Company can earn through cash or share payments, incurring exploration and evaluation expenditures or combinations thereof. Exploration and evaluation asset acquisition costs including option payments are capitalized. Exploration expenditures incurred prior to the determination of the feasibility of mining operations and a decision to proceed with development are recorded in profit or loss. When the existence of a mineral reserve on a property has been established, future acquisition, exploration and development costs will be capitalized for that property, then amortized using the unit-of-production method following commencement of production.

The business of mining and exploration involves a high degree of risk and there can be no assurance that current exploration programs will result in profitable mining operations. The recoverability of exploration and evaluation expenditures is dependent upon several factors. These include the discovery of economically recoverable reserves, the ability of the Company to obtain the necessary financing to complete the development of these properties, and future profitable production or proceeds from disposition of mineral properties

Financial instruments

Classification and measurement - initial recognition

On initial recognition, all financial assets and liabilities are classified and recorded at fair value, net of attributable transaction costs, except for financial assets and liabilities classified as at fair value through profit or loss ("FVTPL").

Classification and measurement – subsequent to initial recognition

Subsequent measurement of financial assets and liabilities depends on their classification and measurement basis.

Financial Assets

Subsequent to initial recognition, financial assets are measured at amortized cost, fair value through other comprehensive income, or fair value through profit or loss, depending on the business model in which a financial asset is managed and its contractual cash flow characteristics.

(formerly Lexston Life Sciences Corp.)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED MAY 31, 2024 AND 2023
(Expressed in Canadian dollars)

3. MATERIAL ACCOUNTING POLICIES (continued)

A financial asset is measured at amortized cost if both of the following conditions are met:

- a) the financial asset is held within a business model whose objective is to hold financial assets in order to collect contractual cash flows; and
- b) the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

A financial asset shall be measured at fair value through other comprehensive income if both of the following conditions are met:

- a) the financial asset is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets; and
- b) the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

Financial assets that do not meet the above conditions are classified as fair value through profit or loss. The Company's cash and accounts receivable are measured at amortized cost. The Company's investment is measured at FVTPL.

Financial Liabilities

Subsequent to initial recognition, financial liabilities are measured at amortized cost, unless designated as fair value through profit or loss. The Company's accounts payable and accrued liabilities and amounts due to related party are measured at amortized cost.

Impairment of Financial Assets

The Company applies the expected credit loss ("ECL") model to its financial assets measured at amortized cost. Under the ECL model, loss allowances are measured on either of the following bases:

- 12-month ECLs: these are ECLs that result from possible default events within the 12 months after the reporting date; and
- lifetime ECLs: these are ECLs that result from all possible default events over the expected life
 of a financial instrument.

Upon recognition of a financial asset, 12-month ECLs are recognized in the consolidated statement of operations and a loss allowance is established. At each reporting date, if the credit risk associated with a financial asset has increased significantly and is not considered low, lifetime ECLs are recognized in the consolidated statement of operations.

Impairment of non-financial assets

At the end of each reporting period, the Company reviews the carrying amounts of long-lived assets to determine whether there is an indication that those assets have suffered an impairment. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment charge (if any). The Company's long-lived assets consist of property and equipment, and investment.

The recoverable amount used for this purpose is the higher of the fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset.

(formerly Lexston Life Sciences Corp.)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED MAY 31, 2024 AND 2023
(Expressed in Canadian dollars)

3. MATERIAL ACCOUNTING POLICIES (continued)

If the recoverable amount of an asset is estimated to be less than its recorded amount, the recorded amount of the asset is reduced to its recoverable amount. An impairment charge is recognized immediately in the consolidated statements of operations, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Where an impairment loss subsequently reverses, the carrying amount of the asset is increased to the revised estimate of its recoverable amount, to a maximum amount equal to the carrying amount that would have been determined had no impairment loss been recognized for the asset in prior years.

Business combinations

The Company evaluates acquisitions to determine whether it is a business combination or an asset acquisition. The Company accounts for business combinations under the acquisition method of accounting. The Company includes the results of operations of acquired businesses in its consolidated financial statements as of the respective dates of acquisition. The purchase price is allocated to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date, with the excess recorded to goodwill.

The determination of fair value requires considerable judgment and is sensitive to changes in the underlying assumptions. The Company's estimates are preliminary and subject to adjustment, which may result in material changes to the final valuation. During the measurement period, which will not exceed one year from closing, the Company may continue to obtain information to assist in finalizing the acquisition date fair values. Any qualifying changes to the preliminary estimates will be recorded as adjustments to the respective assets and liabilities, with any residual amounts allocated to goodwill. Acquisition costs are expensed as incurred, unless they qualify to be treated as debt issue costs, or as cost of issuing equity securities.

Asset acquisitions are accounted for using a cost accumulation model, with the cost of the acquisition allocated to the acquired assets based on their relative fair values. Goodwill is not recognized in an asset acquisition.

Income taxes

(i) Current income taxes

Current income tax assets and liabilities for the current and prior periods are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted at the end of each reporting period.

(ii) Deferred income tax

Deferred income tax is provided using the statement of financial position method on temporary differences at the reporting date between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes. The carrying amount of deferred income tax assets is reviewed at the end of each reporting period and recognized only to the extent that it is probable that sufficient taxable income will be available to allow all or part of the deferred income tax asset to be utilized. Deferred income tax assets and liabilities are measured at the tax rates that are expected to apply to the year when the asset is realized or the liability is settled based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred income tax assets and deferred income tax liabilities are offset, if a legally enforceable right exists to set off current tax assets against current income tax liabilities and the deferred income taxes relate to the same taxable entity and the same taxation authority.

(formerly Lexston Life Sciences Corp.)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED MAY 31, 2024 AND 2023
(Expressed in Canadian dollars)

3. MATERIAL ACCOUNTING POLICIES (continued)

Share capital

Proceeds received on the issuance of units, consisting of common shares and warrants, are allocated first to common shares based on the market trading price of the common shares at the time the units are issued, and any excess is allocated to warrants. Incremental costs directly attributed to the issuance of common shares are shown in equity as a reduction, net of tax, of the proceeds received on issue. Shares issued for non-monetary consideration are valued based on the fair value of the goods or services received unless the fair value of the shares are a more reliable measure.

Share-based payments

The Company grants share-based awards to employees, directors, and consultants as an element of compensation. The fair value of the awards is recognized over the vesting period as share-based compensation expense and share-based payment reserve. The fair value of share-based payments is determined using the Black-Scholes option pricing model with estimates at the date of the grant. At each reporting date prior to vesting, the cumulative expense representing the extent to which the vesting period has expired and management's best estimate of the awards that are ultimately expected to vest is computed. The movement in cumulative expense is recognized in the consolidated statement of operations with a corresponding entry within equity, against share-based payment reserve. No expense is recognized for awards that do not ultimately vest.

When stock options or warrants are exercised, the proceeds received, together with any related amount in share-based payment reserve, are credited to share capital. When stock options or warrants expire unexercised, the fair value of the options or warrants is credited to deficit, with an offsetting reduction in the share-based payment reserve.

Share-based payment arrangements in which the Company receives goods or services as consideration for its own equity instruments are accounted for as equity-settled share-based payment transactions, unless the fair value cannot be estimated reliably. If the Company cannot reliably estimate the fair value of the goods or services received, the Company will measure their value by reference to the fair value of the equity instruments granted.

Loss per share

Basic loss per share is computed using the weighted average number of common shares outstanding during the period. The treasury stock method is used for the calculation of diluted loss per share. Stock options, share purchase warrants, and other equity instruments are dilutive when the average market price of the common shares during the period exceeds the exercise price of the options, warrants and other equity instruments. As at May 31, 2024, the Company had 27,011,653 (2023 – 24,750,359) potentially dilutive shares outstanding.

Foreign currency translation

The functional and reporting currency is the Canadian dollar. Transactions denominated in foreign currencies are translated using the exchange rate in effect on the transaction date or at an average rate. Monetary assets and liabilities denominated in foreign currencies are translated at the rate of exchange in effect at the consolidated statement of financial position date. Non-monetary items are translated using the historical rate on the date of the transaction. Foreign exchange gains and losses are included in the consolidated statement of operations.

Discontinued operations

A discontinued operation is a component of the Company that has been disposed of or is classified as held for sale and that represents a separate major line of business or geographical area of operations, is part of a single coordinated plan to dispose of such a line of business or area of operations, or is a subsidiary acquired exclusively with a view to resale. The results of discontinued operations are presented separately in the profit or loss.

(formerly Lexston Life Sciences Corp.)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED MAY 31, 2024 AND 2023
(Expressed in Canadian dollars)

3. MATERIAL ACCOUNTING POLICIES (continued)

New accounting standards and interpretations

The Company adopted the following amendments to accounting standards, which are effective for annual periods beginning on or after January 1, 2023:

Disclosure of accounting policies - amendments to IAS 1 and IFRS Practice Statement 2

The amendments to IAS 1 Presentation of financial statements and IFRS Practice Statement 2 Making materiality judgments provide guidance and examples to help entities apply materiality judgments to accounting policy disclosures. The amendments aim to help entities provide accounting policy disclosures that are more useful by replacing the requirement for entities to disclose their 'significant' accounting policies with a requirement to disclose their 'material' accounting policies and adding guidance on how entities apply the concept of materiality in making decisions about accounting policy disclosures. The amendments have had an impact on the Company's disclosures of accounting policies, but not on the measurement, recognition or presentation of any items in the Company's consolidated financial statements.

4. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT

Credit risk

Credit risk is the risk of potential loss to the Company if the counterparty to a financial instrument fails to meet its contractual obligations. The Company's credit risk is primarily attributable to its liquid financial assets which is primarily cash. The Company limits exposure to credit risk on liquid financial assets through maintaining its cash with high-credit quality financial institutions. The Company's cash is held with a major Canadian-based financial institution. The carrying amount of financial assets represents the maximum credit exposure.

The Company is exposed to various financial instrument risks and assesses the impact and likelihood of these exposures. These risks include liquidity risk, credit risk, price risk, currency risk and interest rate risk. Where material, these risks are reviewed and monitored by the Board of Directors.

Fair values

Assets and liabilities measured at fair value on a recurring basis were presented on the Company's consolidated statement of financial position as at May 31, 2024 as follows:

	Fair Value Measurements Using		_	
	Quoted prices in	Significant		
	active markets	other	Significant	
	for identical	observable	unobservable	
	instruments	inputs	inputs	Carrying
	(Level 1)	(Level 2)	(Level 3)	Amount
	\$	\$	\$	\$
Investment		1		1

Fair value measurements of financial instruments are required to be classified using a fair value hierarchy that reflects the significance of inputs used in making the measurements. The levels of the fair value hierarchy are defined as follows:

- Level 1 Quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2 Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.
- Level 3 Inputs for assets or liabilities that are not based on observable market data.

(formerly Lexston Life Sciences Corp.)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED MAY 31, 2024 AND 2023
(Expressed in Canadian dollars)

4. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (continued)

The fair values of other financial instruments, which include cash, accounts receivable, accounts payable and accrued liabilities, and amounts due to related party approximate their carrying values due to the relatively short-term maturity of these instruments.

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company currently settles its financial obligations out of cash. The ability to do this relies on the Company raising debt and equity financing in a timely manner and by maintaining sufficient cash in excess of anticipated needs. The Company has cash of \$390,405 at May 31, 2024 (2023 – \$510,995) in order to meet short-term liabilities of \$39,869 (2023 – \$11,207). There is no assurance that financing will be available or, if available, that such financing will be on terms acceptable to the Company. The Company monitors its risk of shortage of funds by monitoring the maturity dates of its existing liabilities. The Company's accounts payable and amounts due to related parties are all due within one year.

Foreign exchange rate and interest rate risk

The Company is not exposed to any significant foreign exchange rate or interest rate risk.

Capital management

The Company's objectives when managing capital are to safeguard the Company's ability to continue as a going concern, so that it can provide returns for shareholders and benefits for other stakeholders.

The Company depends on external financing to fund its activities. The capital structure of the Company currently consists of cash, and equity comprised of issued share capital. The Company manages the capital structure and makes adjustments to it in the light of changes in economic conditions and the risk characteristics of the underlying assets. In order to maintain or adjust the capital structure, the Company may issue new shares through private placements, or sell assets to fund operations. Management reviews its capital management approach on a regular basis. The Company is not subject to externally imposed capital requirements.

5. ACCOUNTS RECEIVABLE

	2024	2023
	\$	\$
Trade accounts receivable	1,089	25
Taxes receivable	7,968	6,325
	9,057	6,350

(formerly Lexston Life Sciences Corp.)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED MAY 31, 2024 AND 2023
(Expressed in Canadian dollars)

6. PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	Computer equipment \$	Laboratory equipment \$	Total \$_
COST: Balance, May 31, 2022	8,491	143,111	151,602
Disposals	(7,221)	(28,518)	(35,739)
Balance, May 31, 2023	1,270	114,593	115,863
Impairment (Note 14)	(1,270)	(114,592)	(115,862)
Balance, May 31, 2024	_	1	1
ACCUMULATED DEPRECIATION: Balance, May 31, 2022	3,926	39,323	43,249
Amortization Disposals	1,281 (3,937)	28,519 (9,880)	29,800 (13,817)
Balance, May 31, 2023	1,270	57,962	59,232
Amortization Impairment (Note 14)	_ (1,270)	26,394 (84,356)	26,394 (85,626)
Balance, May 31, 2024	_	_	
CARRYING AMOUNT:			
Balance, May 31, 2023		56,631	56,631
Balance, May 31, 2024		1	1

7. EXPLORATION AND EVALUATION ASSETS

	Dory \$	Itza/176 \$	Total \$
Balance, May 31, 2023	-	_	_
Acquisition costs:			
Cash	85,000	100,000	185,000
Common shares	17,500	80,000	97,500
Staking	· —	14,985	14,985
Balance, May 31, 2024	102,500	194,985	297,485

Dory Property

The Company entered into a mineral property option agreement dated January 18, 2023 and amended May 31, 2023. In order to exercise the option and earn a 51% interest in the Dory Property, which consists of four mineral claims located 25 km west of Port Alberni in British Columbia, the Company must, within six months from the date of acceptance by the Canadian Securities Exchange (the "Exchange") of the option agreement and the change of business of the Company:

- a) pay to the optionor \$85,000 (paid); and
- b) issue to the optionor a total of 250,000 (issued) common shares of the Company.

The Company will earn a further 49% interest in the Dory Property making the total interest of the Company in the Property 100% by:

a) making a cash payment to the optionor in the amount of \$10,000 within one year from the date of the acceptance of the Option Agreement and the change of business of the Company by the Exchange;

(formerly Lexston Life Sciences Corp.)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED MAY 31, 2024 AND 2023
(Expressed in Canadian dollars)

7. **EXPLORATION AND EVALUATION ASSETS** (continued)

- b) incurring expenditures on the Dory Property in the amount of \$100,000 within one year from the date of the acceptance of the Option Agreement and the change of business of the Company by the Exchange; and
- c) issuing to the optionor a total of 250,000 common shares of the Company within one year from the date of the acceptance of the Option Agreement and the change of business of the Company by the Exchange.

The option is subject to 2% net smelter return royalty in favour of the Optionor, 1/2 of which can be repurchased by the Company for \$1,000,000.

Projects Itza and 176 Properties

The Company entered into a mineral property option agreement dated November 27, 2023 with three optionors (the "**Optionors**") to acquire 100% interest in the uranium mineral property, generally known as "Project 176" (claim 103470) and "Project Itza" (claim numbers 103463, 103478 and 103465) located in the Thelon Basin in Nunavut and occupying a total area of 5,661.93 hectares (the "**Property**").

To exercise the option and earn the 100% interest in the Property, the Company has to pay a total of \$400,000 and issue a total of 6,000,000 shares to the Optionors over a period of two years as follows:

- a) upon the execution of the Agreement to pay \$10,000 (paid);
- b) sixty days from the date of the Agreement to pay \$90,000 (paid) and issue 1,000,000 shares (issued);
- c) within one year from the date of the Agreement to pay \$100,000 and issue 2,000,000 shares; and
- d) within two years from the date of the Agreement to pay \$200,000 and issue 3,000,000 shares.

The option is subject to a net smelter return royalty payable by the Company to the Optionors equal to 1% on the proceeds from production for all minerals derived from the Property. The Company may elect to purchase 1/2 of the net smelter return royalty from the Optionors at any time upon the payment to the Optionors of \$1,000,000.

During the year ended May 31, 2024, the Company made a non-refundable payment of \$10,000 upon execution of the Agreement.

During the year ended May 31, 2024, the Company staked five new mineral claims totaling 5,688 hectares for \$14,985 which join Projects and 176 making it one contiguous land package totaling 11,350 hectares located within the Thelon Basin.

A summary of the Company's exploration and evaluation expenditures related to all the projects for the year ended May 31, 2024 is as follows:

	Dory	Itza/176	Total
	\$	\$	\$
Geological consulting	_	5,938	5,938
	=	5,938	5,938

(formerly Lexston Life Sciences Corp.)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED MAY 31, 2024 AND 2023
(Expressed in Canadian dollars)

8. INVESTMENT

On July 7, 2021, the Company acquired 750,000 Class C non-voting common shares of Psy Integrated Health Inc. ("Psy Integrated"), a private company incorporated in the province of British Columbia, at \$0.10 per share for \$75,000, representing 13% of the total issued and outstanding shares of Psy Integrated and no voting rights, board representation, or involvement in the day-to-day nature of its operations. The Company's investment in Psy Integrated is recorded as FVTPL.

During the year ended May 31, 2024, the Company recorded an unrealized loss of \$Nil (2023 - \$28,999) on its investment in Psy Integrated, and as at May 31, 2024 Psy Integrated has a carrying value of \$1 (2023 - \$1).

9. SHARE CAPITAL

<u>Authorized</u>

Unlimited number of common shares, voting, without par value.

Escrow Shares

Pursuant to an escrow agreement effective June 7, 2021, a total of 4,260,000 common shares of the Company were deposited into escrow for certain principal shareholders. Under the escrow agreement, 10% of the escrowed common shares were released (on the date of listing) and 15% will be released subsequently every 6 months thereafter over a period of 36 months. As of May 31, 2024, there were 639,000 (2023 – 1,917,000) shares held in escrow. The 639,000 common shares were released subsequent to year end (Note 15).

Share Issuances

Year ended May 31, 2024:

- (a) During the year ended May 31, 2024, the Company issued 6,999,333 units at \$0.06 per unit for proceeds of \$419,960, including 1,973,333 units issued to officers and directors of the Company for proceeds of \$118,400. Each unit consisted of one common share and one share purchase warrant. Each warrant entitles the holder to purchase one common share for a period of two years at \$0.08 per share. As part of the private placement, the Company paid finders' fees of \$10,637 and issued 177,280 brokers warrants under the same terms and conditions as the warrants issued pursuant to the private placement. The value of the brokers warrants amounted to \$13,005 based on the value of the equity instruments issued. The Company also recorded \$7,000 in legal fees associated to the financing. These issuance costs were recorded as reduction in share capital and an increase in reserves.
- (b) During the year ended May 31, 2024, the Company issued a total of 2,175,000 common shares at \$0.05 per common share for proceeds of \$108,750 pursuant to the exercise of stock options which resulted in a transfer from share-based payments reserve to share capital of \$94,170.
- (c) During the year ended May 31, 2024, the Company issued a total of 300,000 common shares at \$0.08 per common share for proceeds of \$24,000 pursuant to the exercise of stock options which resulted in a transfer from share-based payments reserve to share capital of \$18,150.
- (d) During the year ended May 31, 2024, the Company issued 900,000 common shares at \$0.075 per common share for proceeds of \$67,500 pursuant to the exercise of share purchase warrants.
- (e) On January 9, 2024, the Company issued 1,000,000 common shares with a fair value of \$80,000 pursuant to the option agreement for the acquisition of Project Iza and Project 176 (Note 7).
- (f) On April 16, 2024, the Company issued 250,000 common shares with a fair value of \$17,500 pursuant to the option agreement for the acquisition of the Dory Property (Note 7).

(formerly Lexston Life Sciences Corp.)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED MAY 31, 2024 AND 2023
(Expressed in Canadian dollars)

9. SHARE CAPITAL (continued)

Year ended May 31, 2023

(a) During the year ended May 31, 2023, the Company issued 18,562,440 units at \$0.05 per unit for proceeds of \$928,122, including 800,000 units issued to officers and directors of the Company for proceeds of \$40,000. Each unit consisted of one common share and one share purchase warrant. Each warrant entitles the holder to purchase one common share for a period of five years at \$0.075 per share. As part of the private placement, the Company paid finders' fees of \$19,880 and issued 397,600 brokers warrants under the same terms and conditions as the warrants issued pursuant to the private placement. The value of the brokers warrants amounted to \$21,576 based on the value of the equity instruments issued. This issuance cost was recorded as reduction in share capital and an increase in reserves.

10. SHARE PURCHASE WARRANTS

The continuity of share purchase warrants is summarized below:

	Weighted average exercise price \$	Number of warrants
Balance, May 31, 2022	0.75	2,790,319
Issued pursuant to private placement	0.075	18,562,440
Broker warrants issued pursuant to private placement	0.075	397,600
Balance, May 31, 2023	0.16	21,750,359
Issued pursuant to private placement	0.08	6,999,333
Broker warrants issued pursuant to private placement	0.08	177,280
Expired	0.75	(2,790,319)
Exercised	0.075	(900,000)
Balance, May 31, 2024	0.08	25,236,653

The following table summarizes the warrants outstanding and exercisable at May 31, 2024:

	Weighted average remaining		Number of
Expiry date	contractual life (years)	Exercise price	warrants
July 4, 2027	2.21	\$0.075	18,060,040
May 15, 2026	0.56	\$0.08	7,176,613
	2.77		25,236,653

As at May 31, 2024, the weighted average remaining contractual life of all warrants outstanding was 2.77 years (May 31, 2023 – 3.59).

The broker warrants issued pursuant to private placement during the year ended May 31, 2024 were valued using the Black-Scholes option pricing model with the following assumptions: Annualized volatility of 143% (2023 - 124%); risk-free interest rate of 4.18% (2023 - 3.04%); expected life of 2 years (2023 - 5 years); and no expected dividends.

(formerly Lexston Life Sciences Corp.)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED MAY 31, 2024 AND 2023
(Expressed in Canadian dollars)

11. STOCK OPTIONS

The Company has a Stock Option Plan whereby stock options are granted in accordance with the policies of regulatory authorities at an exercise price equal to the market price of the Company's stock on the date of the grant and, unless otherwise stated, vest on the grant date and with a term not to exceed five years. Under the plan, the board of directors may grant up to 10% of the issued number of shares outstanding as at the date of the stock option grant.

	Weighted average exercise price \$	Number of stock options
Outstanding, May 31, 2022	0.69	796,000
Granted Cancelled	0.05 0.69	3,000,000 (796,000)
Outstanding, May 31, 2023	0.05	3,000,000
Granted Exercised	0.08 0.05	1,250,000 (2,475,000)
Outstanding and exercisable, May 31, 2024	0.07	1,775,000

Additional information regarding stock options outstanding as at May 31, 2024 is as follows:

Expiry date	Weighted average remaining contractual life (years)	Exercise price \$	Number of Stock options outstanding	Number of Stock options exercisable
October 5, 2027 January 11, 2029	1.56 2.47	0.05 0.08	825,000 950,000	825,000 950,000
	4.03		1,775,000	1,775,000

During the year ended May 31, 2024, the Company recognized share-based compensation of \$75,625 (2023 - \$129,886) on the vesting of stock options to directors, officers, and consultants, of which \$18,150 (2022 - \$45,460) pertains to officers and directors of the Company. The weighted average fair value of options granted during the year ended May 31, 2024, was \$0.08 (May 31, 2023 – 0.05) per option. The fair value of the share price for stock options exercised for the year ended May 31, 2024 was 0.05 (2023 - 0.05) per share.

Share-based compensation is determined using the Black-Scholes option pricing model with the following assumptions and assuming no expected dividends or forfeiture rates:

	2024	2023
Annualized volatility	133%	130%
Risk-free interest rate	3.31%	3.49%
Expected life	5 years	5 years

As at May 31, 2024, there was \$Nil (2023 - \$Nil) of unrecognized share-based compensation related to unvested stock options.

(formerly Lexston Life Sciences Corp.)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED MAY 31, 2024 AND 2023
(Expressed in Canadian dollars)

12. RELATED PARTY TRANSACTIONS

Key Management Compensation

Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Company, directly or indirectly. Key management personnel include the Company's executive officers and Board of Director members.

	2024	2023
	\$	\$
Consulting fees	22,500	20,000
Management fees	69,524	218,825
Salaries and benefits		22,725
Share-based compensation	18,150	45,460

- (a) As at May 31, 2024, the Company prepaid \$Nil (2023 \$22,500) consulting fees to a director. These fees were deferred until the Company completed the Change of Business and accepted by the Exchange.
- (b) During the year ended May 31, 2024, the Company incurred \$22,500 (2023 \$20,000) of consulting fees to a director of the Company.
- (c) During the year ended May 31, 2024, the Company incurred \$69,524 (2023 \$170,825) of management fees to the Chief Executive Officer of the Company.
- (d) During the year ended May 31, 2024, the Company incurred \$Nil (2023 \$48,000) of management fees to the Chief Financial Officer of the Company.
- (e) During the year ended May 31, 2024, the Company incurred \$Nil (2023 \$7,725) of salaries and benefits to two former directors of the Company.
- (f) During the year ended May 31, 2024, the Company disposed of equipment to former director/employee a total of \$Nil (2023 \$15,000) of equipment in lieu of notice of termination.

Insider Participation in Private Placements

A summary of insider participation in the Company's private placements for the year ended May31, 2024 is as follows:

Insider	Number of Units	Price \$	Proceeds \$
Jagdip Bal	1,000,000	0.06	60,000
Jatinder Manhas	166,667	0.06	10,000
Clinton Sharples (First Growth Management)	640,000	0.06	38,400
Clinton Sharples	166,666	0.06	10,000

13. INCOME TAXES

The tax effect computed by applying Canadian federal and provincial statutory rate of 27% of the significant temporary differences, which comprise deferred income tax assets and liabilities, are as follows:

	2024 \$	2023
Income tax recovery at statutory rate	(234,000)	(299,000)
Tax effect of: Permanent differences and other Change in unrecognized deferred income tax assets Change in opening tax balances Share issue costs	20,000 219,000 — (5,000)	36,000 266,000 (3,000)
Income tax provision	_	_

(formerly Lexston Life Sciences Corp.)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED MAY 31, 2024 AND 2023
(Expressed in Canadian dollars)

13. **INCOME TAXES** (continued)

The significant components of deferred income tax assets and liabilities are as follows:

	2024	2023
	\$	\$
Deferred income tax assets		_
Non-capital losses carried forward	929,000	748,000
Property and equipment	68,000	41,000
Exploration and evaluation assets	19,000	_
Share issuance costs	4,000	_
Unrecognized deferred income tax assets	(1,020,000)	(789,000)
Net deferred income tax assets	_	_

As at May 31, 2024, the Company has non-capital losses carried forward of approximately \$3,192,000 which are available to offset future years' taxable income and expire as follows:

	\$
2040	6,000
2041	440,000
2042	1,157,000
2043	919,000
2044	670,000
	3,192,000

14. DISCONTINUED OPERATIONS

During the year ended May 31, 2024, the Company discontinued its research and development of pharmaceutical products, biosciences research and cannabis testing from its two wholly owned subsidiaries, Egret and Zen. Consequently, as at May 31, 2024, assets and liabilities allocable to Egret and Zen were classified as a disposal group. Revenue and expenses, gains and losses relating to the discontinuation of the business line have been eliminated from the Company's continuing operations and are shown as a single line item in the consolidated statements of operations and comprehensive loss.

A summary of the Company's net loss from discontinued operations for the years ended May 31, 2024 and 2023 is as follows:

	2024	2023
	\$	\$
Amortization	26,394	29,800
Consulting	<u>-</u>	10,580
Impairment of property and equipment	30,236	_
Loss on disposal of equipment	<u>-</u>	5,922
Management fees	30,000	30,000
Office	8,794	17,669
Rent	38,007	34,268
Research and development (recovery)	· -	(19,167)
Salaries and benefits	_	33,604
	133,431	142,676

(formerly Lexston Life Sciences Corp.)
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED MAY 31, 2024 AND 2023
(Expressed in Canadian dollars)

14. **DISCONTINUED OPERATIONS** (continued)

A summary of the carrying values of the assets and liabilities in the disposal group is as follows:

	2024	2023
	\$	\$
Assets		
Cash	6,073	1,968
Accounts receivable	4,964	1,469
Prepaid expenses and advances	2,500	3,126
Property and equipment	1	56,631
Liabilities		
Accounts payable and accrued liabilities	7,505	10,832

The consolidated statement of cash flows for the year ended May 31, 2024 was not restated to present the cash flows from the discontinued operations separately, as the Company elected to provide this information in the present note. The cash flows from the discontinued operations of the disposal group for the years ended May 31, 2024 and 2023 are presented in the following table:

	2024 \$	2023 \$
Cash flows provided by (used in) operating activities	4,105	(16,245)
Increase (decrease) in cash	4,105	(16,245)

15. SUBSEQUENT EVENTS

Subsequent to May 31, 2024, the Company:

- a) released 639,000 common shares held in escrow (Note 9).
- b) granted 2,000,000 incentive stock options to consultants of the Company exercisable at \$0.09 per common share for a period of five years.
- c) Issued 2,882,500 common shares for the exercise of 2,882,500 warrants at \$0.075 for total proceeds of \$216,187.